Patents Assigned to OLATEC THERAPEUTICS, INC.
  • Methods for treating breast cancer
    Patent number: 12582628
    Abstract: The present invention is directed to a method of treating breast cancer. The method comprises administering to a subject in need thereof an effective amount of dapansutrile, or a pharmaceutically acceptable solvate thereof. The method optionally comprises further administering to the subject an effective amount of a checkpoint inhibitor.
    Type: Grant
    Filed: April 13, 2022
    Date of Patent: March 24, 2026
    Assignee: OLATEC THERAPEUTICS, INC.
    Inventors: Charles A. Dinarello, Isak Tengesdal
  • Method for treating diabetes
    Patent number: 12569463
    Abstract: The present invention is directed to a method for treating diabetes. The method comprises administering to a subject in need thereof dapansutrile, or a pharmaceutically acceptable solvate thereof, in an effective amount. Oral administration is a preferred route of administration.
    Type: Grant
    Filed: September 22, 2022
    Date of Patent: March 10, 2026
    Assignee: OLATEC THERAPEUTICS, INC.
    Inventors: Charles A. Dinarello, Carlo Marchetti, Marc Y. Donath
  • Methods for treating cardiovascular diseases
    Patent number: 12318361
    Abstract: The present invention is directed to a method for treating cardiovascular diseases such as acute myocardial infarction, atherosclerosis, heart failure, stroke, thrombosis, carditis (including acute myocarditis, acute pericarditis and complicated pericarditis), cardiac allograft rejection, cardiomyopathy, and peripheral vascular diseases. The method comprises administering to a subject in need thereof dapansutrile, in an effective amount. A preferred route of administration is oral administration.
    Type: Grant
    Filed: February 7, 2023
    Date of Patent: June 3, 2025
    Assignee: OLATEC THERAPEUTICS, INC.
    Inventors: Carlo Marchetti, Charles A. Dinarello
  • Methods for treating melanoma
    Patent number: 11857529
    Abstract: The present invention is directed to a method for preventing and/or treating melanoma such as superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, and acral lentiginous melanoma. The method comprises administering to a subject in need thereof an effective amount of dapansutrile. The method optionally comprising co-administering anti-PD-1 antibody with dapansutrile. A preferred route of administration is oral administration.
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: January 2, 2024
    Assignee: OLATEC THERAPEUTICS, INC.
    Inventors: Carlo Marchetti, Charles A. Dinarello